

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

cyclin D3 (C-16)

RRID:AB_2259653

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-182, RRID:AB_2259653

Antibody Information

URL: http://antibodyregistry.org/AB_2259653

Proper Citation: Santa Cruz Biotechnology Cat# sc-182, RRID:AB_2259653

Target Antigen: cyclin D3 (C-16)

Host Organism: rabbit

Clonality: polyclonal

Comments: Discontinued: 2016; validation status unknown check with seller; recommendations: Western Blot; ELISA; Immunoprecipitation; Immunofluorescence; Immunohistochemistry; Immunocytochemistry; WB, IP, IF, IHC(P), ELISA

Antibody Name: cyclin D3 (C-16)

Description: This polyclonal targets cyclin D3 (C-16)

Target Organism: Human, Rat, Mouse

Antibody ID: AB_2259653

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-182

Record Creation Time: 20250820T041306+0000

Record Last Update: 20250820T182154+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

Warning: Discontinued: 2016

Discontinued: 2016; validation status unknown check with seller; recommendations: Western Blot; ELISA; Immunoprecipitation; Immunofluorescence; Immunohistochemistry; Immunocytochemistry; WB, IP, IF, IHC(P), ELISA

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Yamauchi T, et al. (2026) Valine availability controls oncogenic cell-cycle progression through translation of D-type cyclins. Biochemical pharmacology, 246, 117706.

Schirripa A, et al. (2025) Cdk6's functions are critically regulated by its unique C-terminus. iScience, 28(2), 111697.

Hydbring P, et al. (2017) Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. Cancer cell, 31(4), 576.